Veracyte (FRA:12V) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:12V Veracyte Inc FRA:12V
80 GF Score
Price €34.91
GF Value €34.08
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Veracyte Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Veracyte  (FRA:12V) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Veracyte Cyclically Adjusted PB Ratio Related Terms


Veracyte Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Veracyte's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte Cyclically Adjusted PB Ratio Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.42 4.29 4.04 4.90 3.93

Veracyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 3.36 4.06 2.83 5.32

FRA:12V vs GRAL, ADPT, CDNA: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, Veracyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Cyclically Adjusted PB Ratio falls into.


FRA:12V
80GF Score
Veracyte Inc FRA:12V
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Veracyte's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Veracyte's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.111/333.9520*333.9520
=15.111

Current CPI (Jun. 2026) = 333.9520.

Veracyte Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.956 241.428 1.322
201612 1.673 241.432 2.314
201703 1.473 243.801 2.018
201706 1.238 244.955 1.688
201709 1.066 246.819 1.442
201712 0.906 246.524 1.227
201803 0.711 249.554 0.951
201806 0.642 251.989 0.851
201809 1.687 252.439 2.232
201812 1.707 251.233 2.269
201903 1.797 254.202 2.361
201906 4.081 256.143 5.321
201909 4.340 256.759 5.645
201912 4.299 256.974 5.587
202003 4.200 258.115 5.434
202006 3.991 257.797 5.170
202009 6.235 260.280 8.000
202012 5.915 260.474 7.584
202103 12.329 264.877 15.544
202106 12.138 271.696 14.919
202109 13.448 274.310 16.372
202112 13.557 278.802 16.239
202203 13.654 287.504 15.860
202206 14.225 296.311 16.032
202209 14.914 296.808 16.780
202212 14.000 296.797 15.753
202303 13.749 301.836 15.212
202306 13.661 305.109 14.952
202309 13.639 307.789 14.798
202312 12.901 306.746 14.045
202403 13.553 312.332 14.491
202406 13.769 314.175 14.636
202409 13.598 315.301 14.402
202412 14.602 315.605 15.451
202503 14.127 319.799 14.752
202506 13.234 322.561 13.701
202509 13.543 324.800 13.925
202512 14.051 324.054 14.480
202603 14.623 330.213 14.789
202606 15.111 333.952 15.111

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Veracyte (FRA:12V) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of €34.91 is trading 2.4% above its estimated GF Value™ of €34.08. GuruFocus considers Veracyte to be Fairly Valued.

Key valuation signals for FRA:12V:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €34.08 vs. price of €34.91 (2.4% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the FRA:12V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges VCYT:USA12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
80GF Score

Get the complete analysis for FRA:12V

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.91
Price
€34.08
GF Value